Takeda, Novartis, Endo, GSK and AstraZeneca 

Medical Marketing & Media’s article Takeda may be poised to expand IBS treatment category offers a closer look, revealing that Phase III results of its Crohn’s and ulcerative colitis medication show positive patient response in a category among patients who have exhausted other options

A media release by Novartis Global highlights about a BioCamp that fosters an idea exchange with leading scientists and well as young entrepreneurs. Novartis Holds Annual Healthcare Entrepreneur Competition to Generate Insight into Healthcare and Innovation of Tomorrow details the three day leadership camp where selected students explore science and innovation

Endo Health Solutions, which manufactures brand name and generic drugs, has been trying to discard its “non-core assets and boost profit through acquisitions” reports Pharmaceutical-technology. Endo Health Solutions acquires Boca Pharmacal for $225m highlights the move to transform Endo into a more focused specialty healthcare company 

According to MediaPost Communications, Pharmaceutical Giant GSK has retained Omnicom’s PHD to handle media planning and buying duties for the US. In PHD, GroupM And Dentsu Get Pieces Of GSK Media GSK outlines the scope of work for the Omnicom and GroupM shops tp include media strategy, planning and buying

A drug for ovarian cancer, which was halted in 2011 by AstraZeneca (AZ), has now progressed to pivotal studies after a change of heart at the pharma giant. PMLiVE’s article, AZ’s Olaprarib Enters Phase III for Ovarian Cancer looks at the trials that will assess the drug as maintenance monotherapy in women who have responded to platinum-based chemotherapy